£1.5 million placing supporting growth of A... | 15-Sep-2025 | 07:00 | RNS |
ACCRUFeR® assigned Priority Review in US by... | 04-Sep-2025 | 07:03 | RNS |
Interim results for the six months ended 30 Jun 25 | 03-Sep-2025 | 14:17 | RNS |
Data published -European Journal of Heart Failure | 27-Aug-2025 | 07:13 | RNS |
Interim results for the six months ended 30 Jun 25 | 21-Aug-2025 | 12:06 | RNS |
Q2 2025 Trading Update | 23-Jul-2025 | 07:00 | RNS |
Result of AGM | 22-May-2025 | 17:06 | RNS |
Audited results for the year ended 31 Dec 2024 | 24-Apr-2025 | 07:06 | RNS |
Licence Agreement in Japan for ACCRUFeR® | 22-Apr-2025 | 07:01 | RNS |
Q1 2025 Trading Update | 17-Apr-2025 | 11:23 | RNS |
ACCRUFeR® launched in Canada | 11-Mar-2025 | 07:00 | RNS |
PDMR Transaction Notification | 13-Feb-2025 | 16:15 | RNS |
Grant of Share Options | 13-Feb-2025 | 07:00 | RNS |
Unaudited full year trading update | 05-Feb-2025 | 07:00 | RNS |
Anders Lundstrom appointed CEO | 27-Jan-2025 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 7.95p |
Change Today | 0.15p |
% Change | 1.92 % |
52 Week High | 9.00 |
52 Week Low | 2.25 |
Volume | 1,628,832 |
Shares Issued | 1,041.69m |
Market Cap | £82.81m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
16:09 | 52,628 @ 8.06p |
15:54 | 3,100 @ 8.08p |
15:49 | 600 @ 8.08p |
15:49 | 600 @ 8.08p |
15:28 | 65,000 @ 8.06p |
You are here: research